uniQureQURE
Recorded

uniQure Guggenheim 3rd Annual Healthcare Innovation Conference

Review the key takeaways and the transcript of this earnings call.

PeriodFY 0Duration23 minParticipants2

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Debjit ChattopadhyayAnalyst

Well, good morning, and thank you for joining Guggenheim's 3rd Annual Healthcare Innovation Conference. I am Debjit, one of the therapeutic analysts, and my privilege to welcome Matt Kapusta, the CEO of uniQure. Thank you so much for joining us and making time for us.

Debjit ChattopadhyayAnalyst

Thanks for having us. Well, obviously, you've had an interesting series of one and a half years, almost close to a decision point at this point.

Debjit ChattopadhyayAnalyst

What is the market missing from the story, and what's the disconnect from your perspective?

Matt KapustaCEO

Yeah. I think that the market right now is pretty locked in on regulatory risk. Honestly, I think that's understandable given the last 18 months that we've had, and given some of the changes that have occurred within the regulatory environment. I think that the market right now is not fully appreciating the significance of the critical unmet need here and the opportunity. I mean, we see this as one of the largest unmet needs within the genetically defined rare disease space. Huntington's is a ferociously devastating disease, and I think that I don't know how much the market understands or appreciates how the HD community sees the risk-benefit. These patients understand the risks associated with transformational medicines, and they really want to be able to make decisions, treatment decisions with their clinicians.

Matt KapustaCEO

We think as we move on through the end of this year and early next year, we're going to talk more about how we see that commercial opportunity and how we think we can be successful, not only in the launch of the product, but long term as well.

Debjit ChattopadhyayAnalyst

The question that we have been getting since the September data update was switching to the Enroll-HD B cohort, and obviously, that was sort of pre-specified on your part. That produced a non-significant cUHDRS outcome and sort of caused confusion with what is the FDA going to actually look at, right? On hindsight, was that the right call, or should we just have stuck to the original cohort?

Matt KapustaCEO

Yeah. No, it was absolutely the right call scientifically, and let me go through this and explain it. Before I do, let me just say that we know what the FDA is going to look at. The FDA is going to look at the data that is in our BLA submission. That data was based on the Enroll-HD, what we're calling Enroll-HD A cut, which was the original cut that we presented in September 2025. The crux of the situation is, Enroll-HD is an ongoing natural history. This natural history is still recruiting and following up patients. The analysis that we presented in September of 2025 was based on the latest data cut that CHDI, the sponsor of that natural history study, had available. That data cut was as of January 2023, and it included about 19,000 HD participants.

Matt KapustaCEO

CHDI does not update this database on a monthly basis, even on an annual basis. In fact, the next update that they did was two and a half years later. That update was done in September of 2025, and that update included an additional two and a half years of follow-up data on the existing patients, plus 6,000 new patients that were recruited in that two-and-a-half-year period. That database not only represented the largest set of data, it was the most recent set of data, and it was the most contemporaneous set of data with the patients in our study. Scientifically, it made sense to use the latest dataset. Now, the second piece of this is that, again, if you remember where we were in the beginning of this year, the FDA had strongly recommended that we do a sham-controlled double-blinded study.

Matt KapustaCEO

We were the ones that proposed doing the four-year analysis, and one of the concerns that they had was around the lack of pre-specification. To make the analysis as clean as possible, we pre-specified the most recent Enroll-HD data cut, and we had no access to the data. That's the reason we did it. Scientifically, it's sound. I will just say that we provided all the context associated with the amount of missing data, and we believe that those are important contexts and considerations that have to be evaluated when interpreting that data. I know we'll probably get into that in a little bit more detail, but that's the background of utilizing the more recent Enroll-HD.

Debjit ChattopadhyayAnalyst

Got it. When you look at that cUHDRS data, it dropped about 0.52 points from year three to year four. TFC remained rock solid, right? How do we get around that discrepancy? Given the focus is going to be on TFC for the primary endpoint for the future in a confirmatory study, where do you think the FDA is going to line up on the overall dataset?

Matt KapustaCEO

Yeah. Let's go through that. The question is, why do we believe there's a durable, robust clinical effect out to 48 months? There's a couple of reasons, and then we can get into the impact potentially of the comparator. Firstly, as you point out, Total Functional Capacity, which is the most important clinical outcome measure for patients, clinicians, and regulatory authorities. It's the primary endpoint of our confirmatory study. That has been rock solid between years three and four. Actually, if you look at the 48-month trends, the patients treated with high-dose AMT-130 haven't even lost, on average, 0.1 points per year. Not even a tenth of a point on average per year have these patients lost. Remember, patients that are diagnosed with Huntington's, I mean, they live 10 to 15 years, right?

Matt KapustaCEO

This is a four-year period, a significant period of time, and they haven't even lost a tenth of a point on average per year, when the patients that are untreated, right, have lost more than a point of Total Functional Capacity. That's very significant. Total Functional Capacity is important because it is not a performance-based test, right? This is a test of how the disease manifests in Huntington's disease patients' lives. This measures, can you hold a job? Can you perform chores in your daily life? Can you balance your checkbook? These are things that are not necessarily impacted on a given day, right? So it tends to be less variable. For the other measures in cUHDRS, they are performance-based tests.

Matt KapustaCEO

You will come in on a given day, you will do finger tapping, you will sit behind a computer, you will do various tasks, and at this point, we are doing them once a year. There is going to tend to be a little bit more variability associated with that. Number one, TFC, which is the most important thing, is rock solid. Number two, through 48 months, we continue to see clear dose-dependent effect. If you look at the high dose compared to the low dose, and you can almost consider the low dose as almost like a quasi-placebo, even though we believe there is minimal clinical effect there, the high dose on the composite UHDRS was more than a point favorable at 48 months compared to the low dose, right? That I think is important.

Matt KapustaCEO

On the cUHDRS, I think that one of the things that you mentioned was the decline between years three and four. The one thing I will say is, it is difficult, it is easy, I should say, to potentially over-interpret one measure in one given year. On cUHDRS, we saw at year one, it had a favorable movement at year one, and year two was unfavorable, year three it was favorable, year four it was unfavorable. We do not interpret this as variations in treatment effect. I mean, the drug working one year, not working another year. If you actually look at the first two-year period, cUHDRS change compared to the second two-year period, it is nearly identical. I think you have to look at it over perhaps longer periods of time.

Debjit ChattopadhyayAnalyst

Got it. Let me just jump the gun here a little bit and talk about the FDA disclosures about a potential AdCom, which is totally logical for the first gene therapy to be approved in Huntington's disease. Historically, we have seen physicians and patients talk about the benefits and risks of the drug. Do you expect a substantial number of your patients who have been treated with the high dose be present and talk about their experience?

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day